Rain Therapeutics Inc Investor Relations Material
Latest events
Q2 2023
Rain Therapeutics Inc
Access the full event backlog
Slides, Transcripts, and Reports from 13,000 public companies
Latest reports from Rain Therapeutics Inc
Access all reports
Rain Oncology Inc. (formerly Rain Therapeutics Inc.) is a biotechnology company focused on developing precision oncology therapies. It targets oncogenic drivers to select patients based on the genetic profile of their tumors. The company's lead product candidate, milademetan, is an oral small-molecule inhibitor designed to block the MDM2-p53 interaction, a key pathway in many cancers. Rain Oncology is also advancing preclinical programs, including a RAD52 inhibitor aimed at exploiting synthetic lethality in certain cancer types with homologous recombination deficiencies. The company is headquartered in Newark, California, and its shares trade on the NASDAQ.
Latest articles
)
Lowe's Companies: Building a One-Stop Shop for Home Improvement
Lowe's Companies began as a single store in 1921 and has steadily expanded its footprint and offerings, now operating 1,750 stores across the U.S.
7 May 2025
)
Greg Abel: Succeeding Warren Buffett at Berkshire Hathaway
After decades working with Warren Buffett and Charlie Munger, Greg Abel was named Buffett’s successor as he steps down in late 2025.
5 May 2025
)
Intuitive Surgical: Enhancing Surgery with Robotic Precision
Intuitive Surgical has revolutionized surgery with robotics, building its dominant position through decades of innovation, validation, and expansion.
2 May 2025
Ticker symbol
RAIN
Country
🇺🇸 United States